Head-to-head · Value Score
Alan Meds vs Aquivia Health
Two GLP-1 deals, scored on the same six factors. Alan Meds lands a Value Score of 90, Aquivia Health a 69. Here's who gives you the honest lower price — and where each one bites back.
Alan Meds
#7 · Grade A · Best Value
Est. first month
$99/mo
Save ~93% vs brand-nameAquivia Health
#251 · Grade C · Watch List
Est. first month
$149/mo
Save ~89% vs brand-nameThe verdict
Alan Meds takes it on Value Score, 90 to 69 — an est. $99/mo first month, with no teaser step-up baked in. Aquivia Health isn't out of it: Shoppers who want clinician-reviewed compounded GLP-1 with optional branded upgrade.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Alan Meds | Aquivia Health |
|---|---|---|
| Value Score | 90 (A) | 69 (C) |
| Est. first month | $99/mo | $149/mo |
| Save vs brand-name | ~93% | ~89% |
| Semaglutide | $99/mo | $149/mo |
| Tirzepatide | $145/mo | $179/mo |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Flat — no step-up |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Alan Meds
Double-digit semaglutide ($99) and a $145 tirzepatide, both nationwide, with an oral route for the needle-shy.
Why it's a deal
- $99 flat semaglutide and a low $145 tirzepatide
- Available in all 50 states
- Offers an oral/sublingual route
The fine print
- Not LegitScript-certified — do your own pharmacy diligence
- Newer operator with a thin public track record
Aquivia Health
Aquivia Health is a clinician-led, self-pay telehealth platform offering compounded GLP-1 therapy with the option to step up to branded Ozempic or Zepbound — an unusual side-by-side most compounded…
Why it's a deal
- Clinical care provided by Open Loop Healthcare Partners, PC — a reused, verified MSO network
- Named leadership: Steven Bishop MD (CMO), Phillip Gray PharmD (Chief Pharmacist), Tom Foster (President)
- Itemized public pricing: compounded semaglutide $149/mo, tirzepatide $179/mo, Ozempic $1,299, Zepbound $1,399
- Both compounded and branded GLP-1s offered side by side — unusual for a compounded provider
- Self-pay model with no insurance required and no separate consultation fee
The fine print
- No public list of states served — you must complete intake to learn if your state qualifies
- No named 503A compounding pharmacy partner, limiting licensure verification
- No LegitScript, PCAB, or BBB trust badges visible
- Brand confusion: site schema names 'CatalystMD' while the customer-facing brand is Aquivia Health
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Alan Meds is ranked on the Alan Meds alternatives board, and the same list for the other side is on alternatives to Aquivia Health.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.